Cardiovascular and Metabolic Disease

Attacking a cluster

Metabolic diseases affect close to one billion people worldwide. Only four years old, the team is combining unparalleled clinical expertise with basic research and a renowned protein engineering technology platform. Our drug discovery teams are poised to deliver innovative therapies for cardiometabolic diseases and are already moving to the clinic.


Our Pipeline

Cardiovascular and Metabolic diseases

Phase 1

Phase 1

  • MEDI5884 cardiovascular
  • MEDI8111 trauma/bleeding

Phase 2

Phase 2

  • MEDI0382 type-2 diabetes/obesity
  • MEDI6012 cardiovascular

Phase 3

Phase 3

Cardiovascular & Metabolic Disease News

Cardiovascular & Metabolic Disease Publications


Join us at MedImmune

Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.